MONTREAL, QUEBEC--(Marketwire - March 22, 2010) - Bio-Solutions Corp. (OTCBB: BISU) Bio-Solutions Corp. is happy to announce that today Dr. Maximilien Arella has been appointed to Bio-Solution's advisory Board.
"Dr. Max Arella is the brainchild behind the development and implementation of GreenEx, our flagship product", says President and CEO, Dr. Chaumillon.
Dr. Arella is a Professor at the Microbiology and Biotechnology Research Centre, INRS - Institut Armand - Frappier, at the University du Quebec in Montreal. Dr. Arella brings with him extensive international experience in the field of molecular biology and monoclonal antibody development. Combining both an experience of researcher and entrepreneur, he is a member of various national and international committees on infectious diseases and expression of recombinant proteins.
Since 1984, Dr. Arella has been scientific advisor and counsellor for Dr. Tetsuo Nakamura, president of the 'Institute of Immunology Co. Ltd.' based in Tokyo, Japan. From 1996 to 2001, Dr. Arella was a founding member and shareholder of Sapientia Therapeutics, a Canadian biotech company, active in the evaluation of an additive boosting cellular immunity.
Since 1998, Dr. Arella has acted as president and shareholder of Perigene Inc, a company who owns platform technologies from INSA-Rouen and from the UTC-Compiegne in France. He also acted as president and shareholder of Sannica Biotech-Pharma since 1999, whose aim is to increase the value of certain platforms coming from Japan (University of Tokyo, Kyoto and Osaka).
His academic research is mainly based in the fields of molecular biology, fundamental aspects and applications of the double-stranded RNA virus, as well as amplification systems for the analysis of human and animal viruses, and cancer markers. Since 1993, Dr. Arella carried out two mandates as chairman of the Virology Research Center of the IAF during which he held the responsibility of managing both the research and the teaching programs.
Dr. Arella holds a Post-doctorate Degree in Biotechnology from the Roche Institute of Molecular Biology in New Jersey, has a Ph.D. in virology from the Institut Armand Frappier / Universite de Rouen and obtained a Master's Degree in Microbiology-Immunology from the Universite de Montreal.
For more information on Bio-Solutions Corp. and its products, please visit the company's website at www.bio-solutionscorp.com
This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Bio-Solutions' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of studies, the ability of the Company to take advantage of business opportunities in the biotechnology industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements and disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except if we are requested by a governmental authority or applicable law.